VILDAVAS-M

VILDAVAS-M is a pharmaceutical tablet formulation containing Vildagliptin 50 mg and Metformin 500 mg. This combination brings together two active pharmaceutical ingredients from different classes of antidiabetic agents in a single oral dosage form. Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while Metformin is a biguanide compound. The formulation is listed within the anti-diabetic segment of the SupriMeda pharmaceutical product portfolio.

Each tablet contains the specified combination of Vildagliptin and Metformin, with the strength clearly identified for professional product selection and pharmaceutical cataloguing. VILDAVAS-M is presented in tablet form and supplied in a pack containing 10 strips of 10 tablets each, making the product details straightforward for inventory identification and procurement documentation.

For hospitals, pharmacies, doctors and other authorised healthcare procurement professionals, VILDAVAS-M can be identified by its brand name, active ingredients, individual strengths and dosage form. These product specifications support accurate catalogue listings and medicine identification across institutional and pharmacy supply channels. The product belongs to the broader category of combination antidiabetic tablet formulations. Please refer to the approved product packaging and prescribing information for the complete product specifications.